Developer docs
API playgroundTry for free, no card

Search company profiles

Polku Therapeutics

Full company profile

uuid0002kr8

Namestring
Polku Therapeutics
Legal namestring
Polku Therapeutics Oy
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Polku Therapeutics Oy is a Helsinki-based, pre-clinical stage biotech founded in 2023 as a spin-out from the University of Helsinki. The company develops first-in-class, orally bioavailable, brain-penetrant small molecules that target the PREP (prolyl oligopeptidase) – PP2A (protein phosphatase 2A) axis — a master regulator of tau homeostasis in the brain. Its compounds are designed as allosteric modulators of a novel binding site on PREP (protein-protein interaction modulation rather than enzyme inhibition), with the goal of restoring the brain's natural ability to clear toxic tau and α-synuclein aggregates, reducing hyperphosphorylated tau, and dampening neuroinflammation via autophagy induction and p38/MAPK modulation.

The company's pipeline spans Discovery through Phase I across four primary neurodegenerative indications — frontotemporal dementia (FTD/MAPT), progressive supranuclear palsy (PSP), Alzheimer's disease (AD), and Parkinson's disease (PD) — plus an exploratory program in traumatic brain injury. Lead compound POLK-38 has demonstrated significant treatment effects on brain tau pathology and spatial learning in the PS19 tauopathy mouse model, while the HUP series (including HUP-46) has shown behavioral benefits in α-synuclein-based Parkinson's disease models and memory-preservation effects in repeated mild traumatic brain injury models. Discovery and lead optimization are executed through an outsourced model with CRO partner ChemDiv, Inc., and the University of Helsinki research groups of Prof. Timo Myöhänen and Adj. Prof. Erik Wallén remain the scientific core.

Polku does not yet generate product revenue. Its business model is the standard pre-clinical biotech playbook: non-dilutive grant funding from foundations (Alzheimer's Association, Rainwater Charitable Foundation, ADDF) and government (Business Finland) supports early R&D, while the company pursues out-licensing deals, co-development partnerships, and potential M&A with larger pharmaceutical companies to advance its programs through IND-enabling studies and clinical development. The company is venture-backed with a €2.7M pre-seed round led by Torrey Pines Investments and Innovestor Life Science Fund, and its stated GTM targets biopharma firms active in CNS preclinical R&D collaborations and life science investors active in seed rounds.

Short descriptiontext

Polku Therapeutics is a Helsinki-based pre-clinical biotech developing first-in-class small molecule modulators of the PREP-PP2A axis to treat tauopathies and other neurodegenerative diseases, including FTD, PSP, AD, and Parkinson's disease, pursuing an out-licensing business model.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHelsinki, Finland
HQ citystring
Helsinki
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CNS drug discovery, small molecule therapeutics, neurodegenerative disease therapy, tau-targeting therapeutics, preclinical biotech
Industry4 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
CNS Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Strategic Partnerships
TypeLicensing Royalties
Description

As a pre-clinical stage biotech, Polku Therapeutics does not yet generate product revenue. The company is pursuing a traditional biotech revenue model centered on licensing its proprietary PREP-PP2A modulator platform to larger pharmaceutical companies, as well as co-development partnerships and M&A transactions, consistent with the track record of its CEO who has executed over 80 commercial deals in licensing, M&A, and strategic partnerships.

polkutx.com
2Non-dilutive Grant Funding
TypeProfessional Services
Description

Polku receives grant funding from organizations such as the Alzheimer's Association, Rainwater Charitable Foundation, and Business Finland to support R&D programs in tau-targeting therapies and breakthrough therapeutics.

polkutx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Polku Therapeutics is a pre-clinical stage biotech that develops first-in-class small molecule therapies targeting the PREP-PP2A axis to treat neurodegenerative diseases. Its lead compound POLK-38 and HUP series ligands address tau aggregation, autophagy dysfunction, and neuroinflammation across tauopathies (FTD, PSP, AD), Parkinson's disease, and traumatic brain injury. The company operates an outsourced drug discovery model and intends to out-license its pipeline to larger pharmaceutical partners for clinical development and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • POLK-38 demonstrated significant treatment effects on brain tau pathology and spatial learning in PS19 tauopathy mouse model
+2 more records
Product overview1 text field

Polku Therapeutics is a Finnish biotech company developing first-in-class disease-modifying therapies for neurodegenerative diseases. The core platform consists of PREP PPI modulators (small molecules) that target the PREP-PP2A axis to restore the brain's natural ability to clear toxic tau aggregates and reduce neuroinflammation. The lead compound POLK-38 is advancing toward IND-enabling studies for tauopathies (FTD/MAPT, PSP, AD), while HUP-46 represents a validated PREP ligand compound with demonstrated efficacy in Parkinson's disease models. The pipeline spans Discovery through Phase I across multiple neurodegenerative indications.

Product and service3 records
1POLK-38
CategorySmall molecule therapeutic candidate
Description

Lead preclinical compound targeting the PREP-PP2A axis for neurodegenerative diseases. Demonstrated positive efficacy on brain tau pathology and spatial learning in PS19 tauopathy mouse model and advancing through discovery/lead optimization toward IND-enabling studies for tauopathies including FTD (MAPT), PSP, and AD.

2HUP-46
CategorySmall molecule therapeutic candidate
Description

Novel PREP ligand that ameliorates behavioral deficits in alpha-synuclein based Parkinson's disease preclinical model. Part of the HUP series of PREP PPI modulators developed for disease-modifying effects.

3PREP PPI Modulator Platform
CategoryTherapeutic platform
Description

First-in-class small molecule platform targeting the PREP-PP2A axis to restore the brain's natural ability to clear toxic tau aggregates and reduce neuroinflammation. Applied across tauopathies, Parkinson's disease, and traumatic brain injury programs through lead compounds such as POLK-38 and HUP-46.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-22
Description

ChemDiv, Inc., a global provider of integrated drug discovery solutions, has deployed its proprietary CNS-focused drug discovery platform to support Polku Therapeutics' program design and optimization of brain-penetrant small-molecule candidates. The partnership has enabled the advancement of Polku's neurodegenerative programs, with ChemDiv supporting lead compound POLK-38 progression.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Polku's scientific roots are in neuropharmacology and medicinal chemistry research at the University of Helsinki. Prof. Timo Myöhänen (Scientific Co-founder, Professor of Pharmacology) and Adj. Prof. Erik Wallén (Principal Investigator in Pharmaceutical Design) conduct their research at the university, forming the scientific foundation of Polku's therapeutic platform.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US biotech pioneering antisense oligonucleotide (ASO) therapies for CNS diseases, including tau-targeting programs. Comparable to Polku as a neurodegeneration therapeutics company, though using RNA-based rather than small molecule approaches.

TypeBroad incumbent
Description

Large pharma with deep CNS franchise and active tau/AD programs (including lecanemab and follow-on tau assets). Comparable to Polku as a major player in neurodegeneration drug development and a likely acquirer/licensing partner for differentiated CNS assets.

TypeEmerging player
Description

Clinical-stage US biotech developing small molecule therapeutics for Alzheimer's disease and other neurodegenerative conditions. Comparable to Polku as a small molecule platform targeting intracellular CNS pathways in AD, though at a more advanced clinical stage.

TypeDirect peer
Description

US biotech developing CNS small molecules for neurological and neuropsychiatric conditions. Comparable to Polku as a CNS-focused small molecule discovery and development company targeting brain-penetrant therapeutics.

TypeDirect peer
Description

Swiss clinical-stage biotech developing vaccines and small molecules against tau, alpha-synuclein, and other neurodegenerative targets. Directly comparable as a tau-focused therapeutics company with multiple modalities aimed at disease modification in AD and related tauopathies.

TypeDirect peer
Description

Clinical-stage biotech developing antibody-based therapies for neurodegenerative diseases including tau (PRX005) and alpha-synuclein. Comparable to Polku as a tau-targeting therapeutics company, though operating in the antibody modality rather than small molecules.

TypeDirect peer
Description

Clinical-stage US biotech developing small molecule and biologic therapies for neurodegeneration, including programs targeting tau, alpha-synuclein, and lysosomal function. Comparable to Polku as a CNS-focused small molecule platform pursuing disease-modifying mechanisms in tauopathies and PD.

8Cassava Sciences
TypeEmerging player
Description

US clinical-stage biotech developing small molecules (simufilam) for Alzheimer's disease. Comparable to Polku as a CNS small molecule platform pursuing disease modification in tauopathies, with a similar focus on intracellular mechanisms.

TypeBroad incumbent
Description

Large pharma with significant neurodegeneration investment, including tau-targeting antibodies (e.g., zagotenemab legacy program) and the recent Prevail Therapeutics gene therapy acquisition. Comparable as a major potential licensing partner for tau assets and a benchmark for CNS deal economics.

10UCB
TypeBroad incumbent
Description

Global biopharma with active CNS pipeline and tau antibody programs. Comparable to Polku as a strategic player in neurodegenerative therapeutics and a plausible out-licensing partner for differentiated CNS small molecule platforms.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Polku Therapeutics

CNS Therapeuticspolku-therapeutics.com

Polku Therapeutics is a Helsinki-based pre-clinical biotech developing first-in-class small molecule modulators of the PREP-PP2A axis to treat tauopathies and other neurodegenerative diseases, including FTD, PSP, AD, and Parkinson's disease, pursuing an out-licensing business model.

What Polku Therapeutics does

Polku Therapeutics Oy is a Helsinki-based, pre-clinical stage biotech founded in 2023 as a spin-out from the University of Helsinki. The company develops first-in-class, orally bioavailable, brain-penetrant small molecules that target the PREP (prolyl oligopeptidase) – PP2A (protein phosphatase 2A) axis — a master regulator of tau homeostasis in the brain. Its compounds are designed as allosteric modulators of a novel binding site on PREP (protein-protein interaction modulation rather than enzyme inhibition), with the goal of restoring the brain's natural ability to clear toxic tau and α-synuclein aggregates, reducing hyperphosphorylated tau, and dampening neuroinflammation via autophagy induction and p38/MAPK modulation.

The company's pipeline spans Discovery through Phase I across four primary neurodegenerative indications — frontotemporal dementia (FTD/MAPT), progressive supranuclear palsy (PSP), Alzheimer's disease (AD), and Parkinson's disease (PD) — plus an exploratory program in traumatic brain injury. Lead compound POLK-38 has demonstrated significant treatment effects on brain tau pathology and spatial learning in the PS19 tauopathy mouse model, while the HUP series (including HUP-46) has shown behavioral benefits in α-synuclein-based Parkinson's disease models and memory-preservation effects in repeated mild traumatic brain injury models. Discovery and lead optimization are executed through an outsourced model with CRO partner ChemDiv, Inc., and the University of Helsinki research groups of Prof. Timo Myöhänen and Adj. Prof. Erik Wallén remain the scientific core.

Polku does not yet generate product revenue. Its business model is the standard pre-clinical biotech playbook: non-dilutive grant funding from foundations (Alzheimer's Association, Rainwater Charitable Foundation, ADDF) and government (Business Finland) supports early R&D, while the company pursues out-licensing deals, co-development partnerships, and potential M&A with larger pharmaceutical companies to advance its programs through IND-enabling studies and clinical development. The company is venture-backed with a €2.7M pre-seed round led by Torrey Pines Investments and Innovestor Life Science Fund, and its stated GTM targets biopharma firms active in CNS preclinical R&D collaborations and life science investors active in seed rounds.

Polku Therapeutics firmographics

Firmographics
Name
Polku Therapeutics
Legal name
Polku Therapeutics Oy
Website
https://polku-therapeutics.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Polku Therapeutics is a Helsinki-based pre-clinical biotech developing first-in-class small molecule modulators of the PREP-PP2A axis to treat tauopathies and other neurodegenerative diseases, including FTD, PSP, AD, and Parkinson's disease, pursuing an out-licensing business model.
Ownership category
akta.pro rank

Polku Therapeutics industry classification

Industry
Product category
CNS Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAFAA
In Vivo Pharmacology (Efficacy/PD Models)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • CNS drug discovery
  • Small molecule therapeutics
  • Neurodegenerative disease therapy
  • Tau-targeting therapeutics
  • Preclinical biotech

Where Polku Therapeutics is headquartered

Location

Headquarters

HQ city
Helsinki
HQ country
Finland
HQ region
Europe

Offices1 record

Markets served

Polku Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and Strategic Partnerships: As a pre-clinical stage biotech, Polku Therapeutics does not yet generate product revenue. The company is pursuing a traditional biotech revenue model centered on licensing its proprietary PREP-PP2A modulator platform to larger pharmaceutical companies, as well as co-development partnerships and M&A transactions, consistent with the track record of its CEO who has executed over 80 commercial deals in licensing, M&A, and strategic partnerships.
  2. Non-dilutive Grant Funding: Polku receives grant funding from organizations such as the Alzheimer's Association, Rainwater Charitable Foundation, and Business Finland to support R&D programs in tau-targeting therapies and breakthrough therapeutics.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Polku Therapeutics product offering

Product offering

Core offering

Polku Therapeutics is a pre-clinical stage biotech that develops first-in-class small molecule therapies targeting the PREP-PP2A axis to treat neurodegenerative diseases. Its lead compound POLK-38 and HUP series ligands address tau aggregation, autophagy dysfunction, and neuroinflammation across tauopathies (FTD, PSP, AD), Parkinson's disease, and traumatic brain injury. The company operates an outsourced drug discovery model and intends to out-license its pipeline to larger pharmaceutical partners for clinical development and commercialization.

Product overview

Polku Therapeutics is a Finnish biotech company developing first-in-class disease-modifying therapies for neurodegenerative diseases. The core platform consists of PREP PPI modulators (small molecules) that target the PREP-PP2A axis to restore the brain's natural ability to clear toxic tau aggregates and reduce neuroinflammation. The lead compound POLK-38 is advancing toward IND-enabling studies for tauopathies (FTD/MAPT, PSP, AD), while HUP-46 represents a validated PREP ligand compound with demonstrated efficacy in Parkinson's disease models. The pipeline spans Discovery through Phase I across multiple neurodegenerative indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • POLK-38 Lead preclinical compound targeting the PREP-PP2A axis for neurodegenerative diseases. Demonstrated positive efficacy on brain tau pathology and spatial learning in PS19 tauopathy mouse model and advancing through discovery/lead optimization toward IND-enabling studies for tauopathies including FTD (MAPT), PSP, and AD.
  • HUP-46 Novel PREP ligand that ameliorates behavioral deficits in alpha-synuclein based Parkinson's disease preclinical model. Part of the HUP series of PREP PPI modulators developed for disease-modifying effects.
  • PREP PPI Modulator Platform First-in-class small molecule platform targeting the PREP-PP2A axis to restore the brain's natural ability to clear toxic tau aggregates and reduce neuroinflammation. Applied across tauopathies, Parkinson's disease, and traumatic brain injury programs through lead compounds such as POLK-38 and HUP-46.

Quantifiable outcome

  • POLK-38 demonstrated significant treatment effects on brain tau pathology and spatial learning in PS19 tauopathy mouse model
  • +2 more outcomes

Companies that use Polku Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Polku Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Polku Therapeutics partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • ChemDiv, Inc.coreTechnology or Integration · 22 June 2026ChemDiv, Inc., a global provider of integrated drug discovery solutions, has deployed its proprietary CNS-focused drug discovery platform to support Polku Therapeutics' program design and optimization of brain-penetrant small-molecule candidates. The partnership has enabled the advancement of Polku's neurodegenerative programs, with ChemDiv supporting lead compound POLK-38 progression.
  • University of HelsinkicoreStrategic or Co-development PartnerPolku's scientific roots are in neuropharmacology and medicinal chemistry research at the University of Helsinki. Prof. Timo Myöhänen (Scientific Co-founder, Professor of Pharmacology) and Adj. Prof. Erik Wallén (Principal Investigator in Pharmaceutical Design) conduct their research at the university, forming the scientific foundation of Polku's therapeutic platform.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Polku Therapeutics competitors and assessment

Company assessment

Direct peers

  • Ionis Pharmaceuticals: US biotech pioneering antisense oligonucleotide (ASO) therapies for CNS diseases, including tau-targeting programs. Comparable to Polku as a neurodegeneration therapeutics company, though using RNA-based rather than small molecule approaches.
  • Sage Therapeutics: US biotech developing CNS small molecules for neurological and neuropsychiatric conditions. Comparable to Polku as a CNS-focused small molecule discovery and development company targeting brain-penetrant therapeutics.
  • AC Immune: Swiss clinical-stage biotech developing vaccines and small molecules against tau, alpha-synuclein, and other neurodegenerative targets. Directly comparable as a tau-focused therapeutics company with multiple modalities aimed at disease modification in AD and related tauopathies.
  • Prothena: Clinical-stage biotech developing antibody-based therapies for neurodegenerative diseases including tau (PRX005) and alpha-synuclein. Comparable to Polku as a tau-targeting therapeutics company, though operating in the antibody modality rather than small molecules.
  • Denali Therapeutics: Clinical-stage US biotech developing small molecule and biologic therapies for neurodegeneration, including programs targeting tau, alpha-synuclein, and lysosomal function. Comparable to Polku as a CNS-focused small molecule platform pursuing disease-modifying mechanisms in tauopathies and PD.

Broad incumbents

  • Biogen: Large pharma with deep CNS franchise and active tau/AD programs (including lecanemab and follow-on tau assets). Comparable to Polku as a major player in neurodegeneration drug development and a likely acquirer/licensing partner for differentiated CNS assets.
  • Eli Lilly: Large pharma with significant neurodegeneration investment, including tau-targeting antibodies (e.g., zagotenemab legacy program) and the recent Prevail Therapeutics gene therapy acquisition. Comparable as a major potential licensing partner for tau assets and a benchmark for CNS deal economics.
  • UCB: Global biopharma with active CNS pipeline and tau antibody programs. Comparable to Polku as a strategic player in neurodegenerative therapeutics and a plausible out-licensing partner for differentiated CNS small molecule platforms.

Emerging players

  • Cognition Therapeutics: Clinical-stage US biotech developing small molecule therapeutics for Alzheimer's disease and other neurodegenerative conditions. Comparable to Polku as a small molecule platform targeting intracellular CNS pathways in AD, though at a more advanced clinical stage.
  • Cassava Sciences: US clinical-stage biotech developing small molecules (simufilam) for Alzheimer's disease. Comparable to Polku as a CNS small molecule platform pursuing disease modification in tauopathies, with a similar focus on intracellular mechanisms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Polku Therapeutics social profiles

Digital presence

Polku Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Polku Therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Polku Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Polku Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Polku Therapeutics

What does Polku Therapeutics do?

Polku Therapeutics is a pre-clinical stage biotech that develops first-in-class small molecule therapies targeting the PREP-PP2A axis to treat neurodegenerative diseases. Its lead compound POLK-38 and HUP series ligands address tau aggregation, autophagy dysfunction, and neuroinflammation across tauopathies (FTD, PSP, AD), Parkinson's disease, and traumatic brain injury. The company operates an outsourced drug discovery model and intends to out-license its pipeline to larger pharmaceutical partners for clinical development and commercialization.

Is Polku Therapeutics a public or private company?

Polku Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Polku Therapeutics founded?

Polku Therapeutics was founded in 2023. It employs 1 to 10 people.

Where is Polku Therapeutics based?

Polku Therapeutics is headquartered in Helsinki, Finland, in the Europe region.

How does Polku Therapeutics make money?

Two revenue lines are on record. Licensing and Strategic Partnerships are the primary driver. The others are non-dilutive Grant Funding.

Who are Polku Therapeutics's main competitors?

Direct peers on record are Ionis Pharmaceuticals, Sage Therapeutics, AC Immune, Prothena and Denali Therapeutics. Broad incumbents are Biogen, Eli Lilly and UCB. Emerging players are Cognition Therapeutics and Cassava Sciences.

Does Polku Therapeutics have an API?

No public API is recorded for Polku Therapeutics.

What industry is Polku Therapeutics in?

Polku Therapeutics's product category is CNS Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig TherapeuticsChemDiv, Inc., a global provider of integrated drug discovery solutions, announced significant milestones achieved through its proprietary CNS-focused drug discovery platform, which has enabled the design and optimization of brain-penetrant small-molecule programs for its partners Polku Therapeutics and Brenig Therapeutics. Polku Therapeutics reported positive efficacy results for its lead compound POLK-38, demonstrating significant treatment effects on brain tau pathology and spatial learning in a PS19 tauopathy mouse model, while Brenig Therapeutics advanced programs targeting LRRK2 and NLRP3 pathways into clinical development. These advancements underscore the platform's capability in supporting discovery programs for complex central nervous system exposure and neurodegenerative diseases.BioSpaceChemDiv, Inc. Highlights Successful Deployment of Proprietary CNS Drug Discovery Platform, Advancing Neurodegenerative Programs for Polku Therapeutics and Brenig TherapeuticsChemDiv announced its CNS drug discovery platform enabled brain-penetrant programs for Polku and Brenig. Polku's POLK-38 showed positive efficacy in the PS19 tauopathy mouse model, and Brenig's LRRK2/NLRP3 programs advanced to clinical development. Polku will present new data at AAIC on July 12, 2026.news.cision.comPolku Therapeutics’ novel compound blocks memory loss after repeated mild traumatic brain injury in preclinical modelA preclinical study published in Experimental Neurology found that Polku Therapeutics' proprietary prolyl oligopeptidase (PREP) ligand compound prevents long-term memory impairment in a model of repeated mild traumatic brain injury. Mice treated with the PREP ligand immediately after each of five repeated injuries showed blocked cognitive deficits three months later, with reduced neuroinflammation and cellular senescence markers. The research, conducted in collaboration with the University of Helsinki, marks the first demonstration that a small-molecule PREP ligand can protect against cognitive decline from repeated concussions, potentially opening new disease-modifying therapeutic pathways.TmcnetExpert Systems Expands Operations in Europe to Support Drug Discovery for Neurodegenerative Diseases with Polku TherapeuticsExpert Systems is expanding in Europe through a collaboration with Polku Therapeutics, a Helsinki-based startup developing treatments for Parkinson's and Alzheimer's diseases. Expert Systems will provide AI-driven computational tools to support Polku's drug discovery, including target identification and candidate optimization. The partnership aims to de-risk and accelerate Polku's development programs.YahooExpert Systems Expands Operations in Europe to Support Drug Discovery for Neurodegenerative Diseases with Polku TherapeuticsExpert Systems is expanding in Europe through a collaboration with Polku Therapeutics, a Helsinki-based startup developing treatments for Parkinson's and Alzheimer's disease. Expert Systems will provide AI-driven computational tools to support Polku's drug discovery, aiming to de-risk and accelerate candidate selection. The partnership is part of Expert Systems' strategy to apply its platform to high-impact research areas.Business & FinancialExpert Systems Expands Operations In Europe To Support Drug Discovery For Neurodegenerative Diseases With Polku TherapeuticsExpert Systems is expanding its European operations through a collaboration with Polku Therapeutics, a Helsinki-based startup developing treatments for Parkinson's and Alzheimer's disease. Expert Systems will provide AI-driven computational tools to support Polku's drug discovery, including target identification and candidate optimization. The partnership aims to accelerate early-stage drug discovery in neuroscience.Dagens industriTorrey Pines Investment and Innovestor’s Life Science Fund Launch Polku TherapeuticsTorrey Pines Investment and Innovestor's Life Science Fund, with Helsinki University Funds, announced pre-seed funding and launch of Polku Therapeutics, a Helsinki-based biotech. The company will develop novel drug treatments for neurodegenerative disorders, based on over a decade of research by Professor Timo Myöhänen and Senior Scientist Erik Wallén at the University of Helsinki.University of HelsinkiSpinout company, Polku Therapeutics Oy advancing new treatment options for Parkinson's and Alzheimer'sPolku Therapeutics Oy, a spinout from the University of Helsinki, is focused on developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company aims to address the lack of treatments that can alter the disease progression and has developed potential PREP ligands that may halt neurodegenerative symptoms. Established in December 2023, Polku Therapeutics plans to partner with global pharmaceutical companies to advance their solutions toward clinical trials.